Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

Brand drugFirst approved 2005

Revlimid(Lenalidomide)Bristol-Myers Squibb Company logoBMY

Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Bristol-Myers Squibb Company

$4.18B

Medicare cost, 2024

Medicare drug plans spent $4.2 billion on Revlimid (lenalidomide) in 2024, for 239,782 prescriptions and refills filled by 38,856 patients. It ranks 10th among all drugs by Medicare drug plan spending. At about $17,426 per prescription it is a high-cost drug. Florida accounts for the most spending ($404.9 million, 10% of the total).

Medicare cost, 2024

$4.18B

+8.3% from 2023

Prescriptions

240K

$17,426.30 per claim

Patients

39K

11,470 prescribers

Total spending, 2024

$4.18B

$107,530.91 per patient

Questions and answers

How much does Medicare spend on Revlimid?

Medicare prescription drug plans paid $4.18B for Revlimid in 2024, for 239,782 prescriptions and refills to 38,856 patients (up 8.3% from 2023). The average cost per claim was $17,426.30.

Which state spends the most on Revlimid?

Florida had the highest Medicare cost for Revlimid in 2024: $404.9M for 23,726 claims, followed by California ($293.3M).

Who prescribes Revlimid the most?

Parameswaren Venugopal, hematology-oncology in Chicago, IL, had the highest Medicare cost for Revlimid in 2024: 544 claims costing $11.2M.

Who makes Revlimid?

Revlimid is made by Bristol-Myers Squibb Company (BMY), listed in the Medicare spending data as Celgene/BMS.

Spending over the years

Medicare spending by year

All plans and makers

Prescriber data: cost by year

Medicare spending on Revlimid was $4.18B in 2024, after a high of $5.94B in 2022.

By state

Where the prescribers practice, 2024

Medicare cost by state

States with the highest cost

Top prescribers of Revlimid, 2024

By Medicare drug cost

PrescriberTypeClaimsPatientsCost
Parameswaren Venugopal Chicago, ILHematology-Oncology54467$11.2M
Zachary Hruska Charlottesville, VANurse Practitioner58762$11.2M
John M Burke Aurora, COHematology-Oncology41852$9.0M
Erica L Campagnaro Ann Arbor, MIHematology428106$7.7M
Areyl D Goff Milwaukee, WINurse Practitioner39588$7.7M
Catharine E Skoog Milwaukee, WIPhysician Assistant41384$7.4M
Keith E Stockerl-Goldstein Saint Louis, MOMedical Oncology35246$7.1M
Kerry L Bondy Ann Arbor, MIPhysician Assistant384100$6.9M
Jayesh Mehta Chicago, ILHematology38160$6.9M
Sarah A Holstein Omaha, NEHematology-Oncology39839$6.7M
Kim A Zawodni Ann Arbor, MINurse Practitioner34790$6.4M
Erica Stevens North Haven, CTNurse Practitioner35072$6.3M
Tara B Anderson New Haven, CTPhysician Assistant35671$6.2M
Claudia E Paba Prada Pembroke Pines, FLHematology-Oncology35040$6.1M
Ami P Ndiaye Charlotte, NCNurse Practitioner323107$5.9M
Patrick A Hagen Maywood, ILHematology-Oncology31742$5.9M
Matthew J Pianko Ann Arbor, MIHematology31882$5.8M
Suzan Rosen Miami, FLNurse Practitioner30666$5.6M
John P Winters III Westbrook, MEHematology-Oncology30733$5.4M
Carol Huff Baltimore, MDMedical Oncology29947$5.2M
Benjamin Derman Chicago, ILHematopoietic Cell Transplantation and Cellular Therapy28037$5.2M
Emerentia A Agyemang Boston, MANurse Practitioner29961$5.2M
Yenny Garcia Miami, FLNurse Practitioner31757$5.1M
Mark A Schroeder Saint Louis, MOHematology-Oncology24830$4.8M
Seth M Maliske Iowa City, IAHematopoietic Cell Transplantation and Cellular Therapy24834$4.7M

Prescriber data by year

YearPrescribersClaimsPatientsCost
202212,171329,25845,546$5.93B
202311,315216,14336,944$3.86B
202411,470239,78238,856$4.18B

Makers, 2024

Spending by manufacturer as listed in the spending data

ManufacturerClaimsSpending
Celgene/BMSBMY logoBMY239,843$4.18B

Medicaid spending by quarter

Amount reimbursed by state Medicaid programs, all states

Amount reimbursed

Codes

National drug codes (packages)
12
RxNorm concept IDs
1242231, 1242233, 1428947, 1429367, 602910
Application numbers
NDA021880

More drugs: Medicare drug spending and the Prescriptions view.

Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.

LinkedInLinkedInXXYouTubeYouTube